Fondaparinux indications: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 1: Line 1:
{{CMG}}
{{CMG}}


==Indications==


'''Fondaparinux sodium''' (Arixtra) Injection is indicated for the prophylaxis of deep vein thrombosis, which may lead to [[pulmonary embolism]]:
'''Fondaparinux sodium''' (Arixtra) Injection is indicated for the prophylaxis of deep vein thrombosis, which may lead to [[pulmonary embolism]]:
Line 11: Line 13:
Fondaparinux sodium (Arixtra) Injection is indicated for:
Fondaparinux sodium (Arixtra) Injection is indicated for:


* the treatment of acute [[deep vein thrombosis]] when administered in conjunction with warfarin sodium, and
* the treatment of acute [[deep vein thrombosis]] when administered in conjunction with [[warfarin sodium]], and
* the treatment of acute [[pulmonary embolism]] when administered in conjunction with warfarin sodium when initial therapy is administered in the hospital.
* the treatment of acute [[pulmonary embolism]] when administered in conjunction with [[warfarin sodium]] when initial therapy is administered in the hospital.





Revision as of 19:05, 14 February 2009

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]


Indications

Fondaparinux sodium (Arixtra) Injection is indicated for the prophylaxis of deep vein thrombosis, which may lead to pulmonary embolism:

Fondaparinux sodium (Arixtra) Injection is indicated for:



Adapted from the FDA Package Insert.